Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement.

  title={Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement.},
  author={Joseph I Davar and Heidi M. Connolly and Martyn Evan Caplin and Marianne Ellen Pavel and Jerome S. Zacks and Sanjeev Bhattacharyya and Daniel J Cuthbertson and Rebecca Dobson and S Grozinsky-Glasberg and Richard Paul Steeds and Giles Dreyfus and Patricia A. Pellikka and Christos G Toumpanakis},
  journal={Journal of the American College of Cardiology},
  volume={69 10},
Carcinoid heart disease is a frequent occurrence in patients with carcinoid syndrome and is responsible for substantial morbidity and mortality. The pathophysiology of carcinoid heart disease is poorly understood; however, chronic exposure to excessive circulating serotonin is considered one of the most important contributing factors. Despite recognition, international consensus guidelines specifically addressing the diagnosis and management of carcinoid heart disease are lacking. Furthermore… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 42 times over the past 90 days. VIEW TWEETS


Publications referenced by this paper.
Showing 1-10 of 89 references

37LBA. Telotristat etiprate is effective in treating patients with carcinoid syndrome that is not adequately controlled by somatostatin analog therapy (the Phase 3 TELESTAR clinical trial)(abstr)

  • MH Kulke, D Hörsch, M Caplin
  • Eur J Cancer 2015;51:S728
  • 2015
1 Excerpt

6LBA: 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1 trial (abstr)

  • J Strosberg, E Wolin, B Cahsen
  • Eur J Cancer 2015;51:S710
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…